Adenosine A2a Receptor Protein-VLP (ADORA2A)
-
- Target Alle Adenosine A2a Receptor (ADORA2A) Proteine anzeigen
- Adenosine A2a Receptor (ADORA2A)
- Protein-Typ
- VLP
-
Spezies
- Human
-
Quelle
- HEK-293 Cells
- Verwendungszweck
- Human ADORA2A Full Length Protein (VLP)
- Sequenz
- Met 1 - Ser 412
- Produktmerkmale
- Human ADORA2A Full Length Protein-VLP is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ser 412 (Accession # P29274-1).
- Endotoxin-Niveau
- 1.0 EU per μg
- Top Product
- Discover our top product ADORA2A Protein
-
Adenosine A2a Receptor (ADORA2A) (AA 1-412) (Active) protein-VLP
ADORA2A Spezies: Human Wirt: HEK-293 Cells VLP > 95 % as determined by HPLC ELISA, Imm, Func, SPR Active
Adenosine A2a Receptor (ADORA2A) proteinADORA2A Spezies: Human Wirt: Mammalian Cells MSP Nanodisc
Adenosine A2a Receptor (ADORA2A) proteinADORA2A Spezies: Human Wirt: HEK-293 Cells Synthetic Nanodisc
Adenosine A2a Receptor (ADORA2A) (AA 1-412) protein (GST tag)ADORA2A Spezies: Human Wirt: Wheat germ Recombinant WB, ELISA, AP, AA
Adenosine A2a Receptor (ADORA2A) (AA 147-267) protein (GST tag)ADORA2A Spezies: Human Wirt: Wheat germ Recombinant WB, ELISA, AP, AA
Adenosine A2a Receptor (ADORA2A) (AA 1-7) protein (Fc Tag)ADORA2A Spezies: Human Wirt: HEK-293 Cells Recombinant The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- PBS, pH 7.4
- Lagerung
- -80 °C
- Informationen zur Lagerung
- -70°C
-
- Target
- Adenosine A2a Receptor (ADORA2A)
- Andere Bezeichnung
- ADORA2A (ADORA2A Produkte)
- Hintergrund
- Adenosine Receptor Subtype A2a (ADORA2A) is a G-protein coupled adenosine receptor encoded by the ADORA2A gene. It is mainly involved in pathophysiological processes including neuroinflammation, synaptic plasticity in glutamatergic synapses and neurogenesis.
- Pathways
- Neurotrophin Signalübertragung, cAMP Metabolic Process, Synaptic Membrane, Feeding Behaviour, Cancer Immune Checkpoints
-
